Avid Bioservices Inc (CDMO)

[entdoc]

Volgoat, thanks for the information. If possible, I am interested in reading the source for "However it has been shown in several studies that humanised antibodies bind antigen much more weakly than the parent murine monoclonal antibody, with reported decreases in affinity of up to several hundredfold [which I do not doubt]", and also for, "Fully human Mab's will only reduce irritation at the dosing site, it is not any more effective, it is actually less effective for mab's". There are several aspects to consider re. this question. In general, I think most investigators would validate/agree with the following: "Fully human antibodies derived from transgenic mice are the current apex of therapeutic antibody development". [MAbs. 2010 May-Jun; 2(3): 256–265.
The immunogenicity of humanized and fully human antibodies
Residual immunogenicity resides in the CDR regions
Fiona A Harding, Marcia M Stickler, Jennifer Razo, and Robert B DuBridge]